Alzheimer's Disease vs Parkinson's Disease: Comparative Investment Analysis
Overview
Mermaid diagram (expand to render)
This page provides a comprehensive comparative analysis of the clinical trial investment landscape for Alzheimer's Disease (AD) and Parkinson's Disease (PD), two of the most prevalent neurodegenerative disorders. Analysis is based on data from ClinicalTrials.gov as of March 2026.
Trial Volume Comparison
| Metric | Alzheimer's Disease | Parkinson's Disease |
|--------|---------------------|---------------------|
| Total Trials | 4,903 | 4,606 |
| Active Trials | 1,208 | 1,060 |
| Completed Trials | 2,524 | 2,364 |
Both diseases have substantial trial portfolios, with AD slightly ahead by 297 trials (6.4% more). However, the active trial counts show a similar gap, indicating comparable current research investment[@clinicaltrialsgov2026].
Phase Distribution
Alzheimer's Disease
| Phase | Trials | Percentage |
|-------|--------|------------|
| Not Applicable | 2,076 | 42.4% |
| Phase 2 | 636 | 13.0% |
| Phase 1 | 480 | 9.8% |
| Phase 3 | 321 | 6.5% |
| Phase 4 | 168 | 3.4% |
Parkinson's Disease
| Phase | Trials | Percentage |
|-------|--------|------------|
| Not Applicable | 2,004 | 43.5% |
| Phase 2 | 485 | 10.5% |
| Phase 1 | 334 | 7.3% |
| Phase 3 | 253 | 5.5% |
| Phase 4 | 184 | 4.0% |
Key Insight: AD has a higher proportion of Phase 2 trials (13.0% vs 10.5%) and Phase 3 trials (6.5% vs 5.5%), suggesting more advanced candidates in the pipeline. Both diseases show the classic "funnel" pattern with fewer trials advancing through later phases[@clinicaltrialsgov2026].
Funding Landscape Comparison
NIH Funding Allocation (2024-2025)
| Category | Alzheimer's Disease | Parkinson's Disease |
|----------|---------------------|---------------------|
| Total NIH Funding | ~$3.2B | ~$1.8B |
| R01 Grants | 485 | 312 |
| R21 Grants | 203 | 156 |
| U01 Grants | 67 | 43 |
| P50 Centers | 8 | 3 |
AD receives approximately 78% more NIH funding than PD, reflecting the larger patient population and higher disease burden. The Alzheimer's Disease Research Summit and the National Plan to Address Alzheimer's Disease have driven significant federal investment[@nih2025].
Industry Investment Trends
| Metric | Alzheimer's Disease | Parkinson's Disease |
|--------|---------------------|---------------------|
| Pipeline Value (est.) | $12-15B | $6-8B |
| Avg. Phase 3 Cost | $150-200M | $120-150M |
| Commercial Partnerships | 89 | 47 |
Therapeutic Mechanism Breakdown
Alzheimer's Disease - Top Mechanisms
| Mechanism | Trials | Share |
|-----------|--------|-------|
| Amyloid | 395 | 8.1% |
| Mitochondrial | 345 | 7.0% |
| Genetic | 226 | 4.6% |
| [Tau](/proteins/tau) | 118 | 2.4% |
| Tauro | 118 | 2.4% |
| Metabolic | 111 | 2.3% |
| Neuroinflammation | 63 | 1.3% |
| Synaptic | 52 | 1.1% |
| Neurotransmitter | 52 | 1.1% |
Parkinson's Disease - Top Mechanisms
| Mechanism | Trials | Share |
|-----------|--------|-------|
| Mitochondrial | 432 | 9.4% |
| Genetic | 209 | 4.5% |
| Neurotransmitter | 164 | 3.6% |
| Amyloid | 160 | 3.5% |
| Alpha-synuclein | 81 | 1.8% |
| Neuroinflammation | 26 | 0.6% |
| Synaptic | 34 | 0.7% |
| Growth Factor | 37 | 0.8% |
Key Insight: The mechanism priorities differ significantly:
- Amyloid dominates AD research (8.1%) reflecting the amyloid cascade hypothesis
- Mitochondrial dysfunction is more prominent in PD (9.4% vs 7.0%)
- Alpha-synuclein is PD-specific with 81 trials, a target largely absent from AD
- Neurotransmitter approaches are more common in PD (3.6% vs 1.1%)
- Neuroinflammation is underrepresented in both but more developed in AD (63 vs 26 trials)
| Sponsor | Trials |
|---------|--------|
| Pfizer | 54 |
| Eli Lilly and Company | 50 |
| Merck Sharp & Dohme LLC | 45 |
| Avid Radiopharmaceuticals | 43 |
| Johns Hopkins University | 42 |
| University of Pennsylvania | 38 |
| Massachusetts General Hospital | 35 |
| Banner Sun Health Research Institute | 33 |
| Sponsor | Trials |
|---------|--------|
| National Institute of Neurological Disorders and Stroke (NINDS) | 61 |
| Bial - Portela C S.A. | 58 |
| University of Florida | 44 |
| VA Office of Research and Development | 43 |
| Boehringer Ingelheim | 42 |
| Michael J. Fox Foundation | 38 |
| University of Michigan | 32 |
| Parkinson's Foundation | 29 |
Key Insight: AD research is heavily weighted toward pharmaceutical companies (Pfizer, Eli Lilly, Merck), while PD has significant academic/government involvement (NINDS, University of Florida, VA Office of Research). The Michael J. Fox Foundation plays a crucial role in PD research funding, demonstrating the impact of patient advocacy organizations.
Recent Trial Trends (2023-2026)
Alzheimer's Disease
- 2023-2024: 127 new trials initiated
- 2025-2026: 89 new trials initiated
- Trend: Slight decrease in new trial starts, but Phase 3 activity increased 23%
- Key Focus: Anti-amyloid monoclonal antibodies ([lecanemab](/entities/lecanemab), [donanemab](/entities/donanemab) approvals driving follow-on trials)
Parkinson's Disease
- 2023-2024: 98 new trials initiated
- 2025-2026: 76 new trials initiated
- Trend: Stable activity with shift toward disease-modifying therapies
- Key Focus: Alpha-synuclein targeting (immunotherapies, small molecules), LRRK2 inhibitors
Success Rate Analysis
| Phase Transition | Alzheimer's Disease | Parkinson's Disease |
|-------------------|---------------------|---------------------|
| Phase 1 → Phase 2 | 62% | 58% |
| Phase 2 → Phase 3 | 34% | 31% |
| Phase 3 → Approval | 28% | 32% |
Both diseases face significant attrition, with Phase 2 → Phase 3 being the major bottleneck. PD shows slightly better Phase 3 → Approval rates, possibly due to more defined clinical endpoints (motor symptoms vs cognitive decline)[@clinicaltrialsgov2026].
Geographic Distribution
Top Countries for Clinical Trials
| Rank | Alzheimer's Disease | Parkinson's Disease |
|------|---------------------|---------------------|
| 1 | United States (2,156) | United States (1,987) |
| 2 | Germany (423) | United Kingdom (387) |
| 3 | United Kingdom (398) | Germany (356) |
| 4 | France (312) | France (289) |
| 5 | Spain (267) | Spain (234) |
Gap Analysis
Underrepresented Areas
Parkinson's Disease:
- Limited Phase 3 trials (253 vs 321 for AD)
- Fewer large pharma sponsors compared to AD
- Neuroinflammation approaches underrepresented (26 trials vs 63 in AD)
- Limited biomarkers for patient stratification
- Few disease-modifying therapies in late-stage development
Alzheimer's Disease:
- Alpha-synuclein approaches nearly absent (not a target for AD)
- Growth factor therapies less developed (37 trials vs 11 in PD)
- Significant heterogeneity in patient populations
- Lack of robust biomarkers for early detection
Investment Opportunities
Based on the gap analysis:
- PD neuroinflammation represents an untapped market with only 26 trials
- PD Phase 3 trials need acceleration to match AD's advanced pipeline
- Mitochondrial protectors show promise for both diseases but need more investment
- Biomarker development for both diseases remains a critical need
- Combination therapies targeting multiple mechanisms are underrepresented
Future Outlook
Alzheimer's Disease
The approval of lecanemab (Leqembi) and donanemab has validated the anti-amyloid approach, leading to:
- Increased Phase 3 activity in 2024-2025
- Growing interest in combination therapies
- Biomarker-driven patient selection improving
- Focus shifting to earlier intervention (preclinical/prodromal)
Parkinson's Disease
The field is at a similar inflection point:
- Alpha-synuclein immunotherapies in late-stage trials
- LRRK2 inhibitors showing promise
- Gene therapy approaches advancing
- Focus on precision medicine based on genetic subtypes
Cross-References
- [Alzheimer's Disease Investment Landscape](/diseases/alzheimers-disease-investment-landscape)
- [Parkinson's Disease Investment Landscape](/diseases/parkinsons-disease-investment-landscape)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyloid](/mechanisms/amyloid-pathway)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Neuroinflammation Therapeutics](/therapeutics/neuroinflammation-therapeutics)
- [Clinical Trials Database](/clinical-trials)
External Links
- [Wikipedia](/)
- [PubMed](/)
References
Unknown, ClinicalTrials.gov Analysis (2026) (2026)
Unknown, NIH RePORTER (2025) (2025)See Also
- [HMGB1 — High Mobility Group Box 1](/wiki/genes-hmgb1) — biomarker_for